502
Participants
Start Date
January 31, 2020
Primary Completion Date
February 5, 2025
Study Completion Date
February 5, 2025
Gemcitabine combined with nab-paclitaxel
"Arm is closed to recruitment.~Nab-paclitaxel is infused over 30-40 min on days 1, 8, 15 of each 28-day cycle. Gemcitabine is infused over 30 min, immediately after completion of nab-paclitaxel infusion, on days 1, 8, 15 of each 28-day cycle.~If one of the chemotherapy medications is held, the other study medications may be given.~Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
Dose -mFOLFIRINOX
"Arm is closed to recruitment.~The following are recommended parameters for infusion timing and sequence, although institutional variation in the administration of the regimen are permitted, as long as drug dosing and modification guidelines are followed. Oxaliplatin and leucovorin are administered concurrently over 30-120 minutes, followed by irinotecan over 30-90 minutes, followed by the infusion of 5-flurouracil. If one of the chemotherapy medications is held, the other study medications may be given. Doses should be re-adjusted if the participant's weight changes by +/- \>10%. If the participant's weight changes by \<10%, no adjustment is necessary unless the site has a standard procedure to adjust doses based upon current weight according to institutional guidelines."
Dose - Pamrevlumab combined with gemcitabine and nab-paclitaxel
"Arm is closed to recruitment.~Pamrevlumab 35mg/kg IV - Cycle 1 (Day 1, 8, 15 of the 28 day cycle) and Cycle 2 and Onward (Day 1 and 15)~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 for every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 for every 28 day cycle"
Dose- Canakinumab and Spartalizumab combined with nab-paclitaxel and gemcitabine
"Arm is closed to recruitment.~Canakinumab 250mg SC- Day 1 of every 28 day cycle~Spartalizumab 400 mg IV - Day 1 of every 28 day cycle~Nab-paclitaxel 125mg/m2 IV - Day 1, 8, 15 of every 28 day cycle~Gemcitabine 1000mg/m2 IV - Day 1, 8, 15 of every 28 day cycle"
Drug: Dose -SM-88
"Arm is closed to recruitment.~460 mg (2 capsules) twice daily of a 28-day cycle along with the administration of methoxsalen, phenytoin and sirolimus."
New York University Langone Medical Center - Perlmutter Cancer Center, New York
Evelyn H. Lauder Breast Center - Memorial Sloan Kettering Cancer Center, New York
Weill Cornell Physicians - Solid Tumor/Gastrointestinal Oncology, New York
Johns Hopkins Medicine - The Sidney Kimmel Comprehensive Cancer Center, Baltimore
Virginia Commonwealth University School of Medicine, Richmond
University of Florida College of Medicine, Gainesville
University of Cincinnati Cancer Institute, Cincinnati
University of Michigan - Rogel Cancer Center, Ann Arbor
The University of Chicago Medical Center, Chicago
The University of Texas Southwestern Medical Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Huntsman Cancer Institute, Salt Lake City
University of New Mexico Comprehensive Cancer Center, Albuquerque
University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla
University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco
Virginia Mason Hospital & Seattle Medical Center, Seattle
Fred Hutchinson Cancer Research Center, Seattle
Cedars-Sinai Medical Center, Los Angeles
Sylvester Comprehensive Cancer Center, Miami
Dana-Farber Cancer Institute, Boston
Mayo Clinic Cancer Center (MCCC), Rochester
Siteman Cancer Center - Washington University Medical Campus, St Louis
University of Pennsylvania - Abramson Cancer Center, Philadelphia
Baylor College of Medicine, Houston
Medical College of Wisconsin, Milwaukee
Pancreatic Cancer Action Network
OTHER